Protein Sciences Corporation
Quick facts
Phase 3 pipeline
- Fluarix Quadrivalent® Influenza Virus Vaccine · Immunology
Fluarix Quadrivalent stimulates the immune system to produce antibodies against four strains of influenza virus, providing protection against seasonal flu infection. - FluBlok Influenza Vaccination · Immunology / Infectious Disease
FluBlok is a recombinant influenza vaccine that stimulates the immune system to produce antibodies against influenza virus surface proteins. - Flublok Quadrivalent Influenza Vaccine · Immunology / Infectious Disease
Flublok Quadrivalent stimulates immune response against four influenza virus strains by presenting recombinant hemagglutinin antigens produced in insect cells. - Flublok® Quadrivalent Influenza Virus Vaccine · Immunology / Infectious Disease
Flublok stimulates the immune system to produce antibodies against four strains of influenza virus by presenting recombinant hemagglutinin antigens.
Phase 2 pipeline
Phase 1 pipeline
- Panblok · Other
- rHA adjuvant
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Protein Sciences Corporation
What is Protein Sciences Corporation's pipeline?
Protein Sciences Corporation has 4 drugs in Phase 3, 1 in Phase 2, 2 in Phase 1. Late-stage candidates include Fluarix Quadrivalent® Influenza Virus Vaccine, FluBlok Influenza Vaccination, Flublok Quadrivalent Influenza Vaccine, Flublok® Quadrivalent Influenza Virus Vaccine.
Related
- Sector hub: All tracked pharma companies